en · de · es · fr · pt
sr9009-notes.peptides6155.com › Data › Sr9009 Identity And Mechanism — Explained

Sr9009 Identity And Mechanism — Explained

By Editorial Desk · published 2026-06-20 · last reviewed 2026-07-10 · Data

This is a working overview of SR9009, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-07-10 and is reviewed periodically as new material appears.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also marketed informally as Stenabolic
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ
Molecular formulaC24H30ClN3O4SApproximate molecular weight 492 g/mol
CAS Registry Number1379686-30-2Identifier for the parent compound
Regulatory statusNot approved for human useProhibited in sport by WADA

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Related pages on this site

Background and Mechanism of SR9009

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

SR9009 Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

Supporting material

The programme is also expected to create over 4 million jobs in the next 4 years (2.5 million direct jobs and 1.5 million indirect jobs). Some economists have criticised the plan, citing Brazil's poor track record of investment quality and worries regarding fiscal responsibility. Of the energy investments, 343 billion will be made through Petrobras, a state-owned corporation notable for its involvement in a corruption scandal during Lula's previous presidency.

uridine monophosphate (UMP)), usually to tyrosine propionylation pyroglutamate formation S-glutathionylation S-nitrosylation S-sulfenylation, reversible covalent addition of one oxygen atom to the thiol group of a cysteine residue to form a sulfenic acid S-sulfinylation, normally irreversible covalent addition of two oxygen atoms to the thiol group of a cysteine residue to form a sulfinic acid S-sulfonylation, normally irreversible covalent addition of three oxygen atoms to the thiol group of a cysteine residue, resulting in the formation of a cysteic acid residue sulfation, the addition of a sulfate group to a tyrosine.

=== Russia === Russia had the most to gain from the Triple Intervention. In the preceding years, Russia had been slowly increasing its influence in the Far East since at least the Treaty of Aigun in 1858 and the building of her warm water port in Asian waters, Vladivostok. The construction of the Trans-Siberian Railway and the acquisition of another warm-water port on the China Seas would enable Russia to consolidate her presence in the region and further expand into Asia and the Pacific. Russia did not believe that the Japanese would be victorious against China in 1894. Port Arthur falling into Japanese hands would undermine its own desperate need for a warm-water port in the East.

=== Flavoring agents === A large number of pyridine compounds are approved as flavoring agents in the EU. These include the three isomeric picolines and several lutidines. Selected representatives are listed in the following table.

Sources: en.wikipedia.org

Supporting material

=== Pesticides === Many pesticides are enzyme inhibitors. Acetylcholinesterase (AChE) is an enzyme found in animals, from insects to humans. It is essential to nerve cell function through its mechanism of breaking down the neurotransmitter acetylcholine into its constituents, acetate and choline. This is somewhat unusual among neurotransmitters as most, including serotonin, dopamine, and norepinephrine, are absorbed from the synaptic cleft rather than cleaved. A large number of AChE inhibitors are used in both medicine and agriculture. Reversible competitive inhibitors, such as edrophonium, physostigmine, and neostigmine, are used in the treatment of myasthenia gravis and in anaesthesia to reverse muscle blockade. The carbamate pesticides are also examples of reversible AChE inhibitors. The organophosphate pesticides such as malathion, parathion, and chlorpyrifos irreversibly inhibit acetylcholinesterase.

The county is named after the ancient Welsh Kingdom of Powys, which in the sixth century AD included the northern two-thirds of the area as well as most of Shropshire, Herefordshire and adjacent areas now in England, and came to an end when it was occupied by Llywelyn ap Gruffudd of Gwynedd during the 1260s. The uplands retain evidence of occupation from long before the Kingdom of Powys, and before the Romans, who built roads and forts across the area. There are 1130 identified burial mounds within the county, of varying styles and ages, dating from 4000 BC to 1000 BC, most of them belonging to the Bronze Age. Of these, 339 are scheduled monuments. Standing stones, most again dating to the Bronze Age, also occur in large numbers, 276 being found across the county, of which 92 are scheduled. From the Iron Age, the county has 90 scheduled hillforts and a further 54 enclosures and settlement sites. Powys is served by the Cambrian Line and Heart of Wales line which offer connections to major towns and cities such as Swansea, Wrexham, Shrewsbury, Birmingham, Wolverhampton, Manchester, Cardiff, Aberystwyth, London and Telford. The county used to be served by key railways such as the Mid-Wales Railway, Oswestry and Newtown Railway, Tanat Valley Light Railway, Llanfyllin Branch, Leominster and Kington Railway, Swansea Vale Railway and the Hereford, Hay and Brecon Railway, all of which offered connections to South Wales, Hereford, Oswestry, North Wales and West Wales but have all since closed.

After a memorable 90th birthday, at which she was surrounded by her now vast family, Zita's habitually-robust health began to fail. She developed inoperable cataracts in both eyes. Her last major family gathering took place at Zizers, in 1987, when her children and grandchildren joined in celebrating her 95th birthday. While visiting her daughter, in summer 1988, she developed pneumonia and spent most of the autumn and winter bedridden. Finally, she called Otto in early March 1989 and told him she was dying. He and the rest of the family travelled to her bedside and took turns keeping her company until she died in the early hours of 14 March 1989. She was 96 years old, and was the last surviving child of Robert, Duke of Parma from both his marriages. Her funeral was held in Vienna on 1 April. The government allowed it to take place on Austrian soil if the cost was borne by the Habsburgs themselves. Zita's body was carried to the Imperial Crypt under Capuchin Church in the same funeral coach she had walked behind during the funeral of Emperor Franz Joseph in 1916. It was attended by over 200 members of the Habsburg and Bourbon-Parma families, and the service had 6,000 attendees including leading politicians, state officials and international representatives, including a representative of Pope John Paul II. Following an ancient custom, the Empress had asked that her heart, which was placed in an urn, stay behind at Muri Abbey, in Switzerland, where the Emperor's heart had rested for decades.

Antioxidants − Many antioxidants are used in food industry as food additives. These compounds react with oxygen and suppress the initiation of the browning process. Also, they interfere with intermediate products of the following reactions and inhibit melanin formation. Ascorbic acid, N-acetylcysteine, L-cysteine, 4-hexylresorcinol, erythorbic acid, cysteine hydrochloride, glutathione are examples of antioxidants that have been studied for their anti-browning properties. Chelating agents − Polyphenol oxidase requires copper as a cofactor for its functionality, thus copper-chelating agents inhibit the activity of this enzyme. Many agents possessing chelating activity have been studied and used in different fields of food industry, such as citric acid, sorbic acid, polyphosphates, hinokitiol, kojic acid, EDTA, porphyrins, polycarboxylic acids, different proteins. Some of these compounds also have other anti-browning effects, such as acidifying or antioxidant. Hinokitiol is used in coating materials for food packaging.

=== Substrate specificity === Under normal circumstances, caspases recognize tetra-peptide sequences on their substrates and hydrolyze peptide bonds after aspartic acid residues. Caspase 3 and caspase 7 share similar substrate specificity by recognizing tetra-peptide motif Asp-x-x-Asp. The C-terminal Asp is absolutely required while variations at other three positions can be tolerated. Caspase substrate specificity has been widely used in caspase based inhibitor and drug design.

Sources: en.wikipedia.org

Notes from published material

Because PCR amplifies the regions of DNA that it targets, PCR can be used to analyze extremely small amounts of sample. This is often critical for forensic analysis, when only a trace amount of DNA is available as evidence. PCR may also be used in the analysis of ancient DNA that is tens of thousands of years old. These PCR-based techniques have been successfully used on animals, such as a forty-thousand-year-old mammoth, and also on human DNA, in applications ranging from the analysis of Egyptian mummies to the identification of a Russian tsar and the body of English king Richard III. Quantitative PCR or real-time PCR (qPCR not to be confused with RT-PCR) methods allow the estimation of the amount of a given sequence present in a sample—a technique often applied to quantitatively determine levels of gene expression. The MIQE guidelines written by professors Stephen Bustin, Michael Pfaffl, Mikael Kubista and colleagues outline how qPCR experiments shall be performed and the results reported. Quantitative PCR is an established tool for DNA quantification that measures the accumulation of DNA product after each round of PCR amplification. qPCR allows the quantification and detection of a specific DNA sequence in real time since it measures concentration while the synthesis process is taking place. There are two methods for simultaneous detection and quantification. The first method consists of using fluorescent dyes that are retained nonspecifically in between the double strands.

The United Kingdom dismissed the warnings of Winston Churchill and a few others about a continuing Marxist-Leninist threat, and opened trade relations and de facto diplomatic recognition in 1922. There was hope for a settlement of the pre-war Tsarist debts, but it was repeatedly postponed. Formal recognition came when the new Labour Party came to power in 1924. All the other countries followed suit in opening trade relations. Henry Ford opened large-scale business relations with the Soviets in the late 1920s, hoping that it would lead to long-term peace. Finally, in 1933, the United States officially recognized the USSR, a decision backed by the public opinion and especially by US business interests that expected an opening of a new profitable market. In the late 1920s and early 1930s, Stalin ordered Marxist-Leninist parties across the world to strongly oppose non-Marxist political parties, labour unions or other organizations on the left, which they labelled social fascists. In the usage of the Soviet Union, and of the Comintern and its affiliated parties in this period, the epithet fascist was used to describe capitalist society in general and virtually any anti-Soviet or anti-Stalinist activity or opinion. Stalin reversed himself in 1934 with the Popular Front program that called on all Marxist parties to join with all anti-Fascist political, labour, and organizational forces that were opposed to fascism, especially of the Nazi variety.

=== Cardiovascular and organ sequelae === Spherocytes have less plasma membrane compliance and fluidity, and this has implications throughout the entirety of circulation within the body, i.e. arteries, arterioles, capillaries, venules, veins, and organs. The lack of compliance and fluidity lead to a higher viscosity value for blood (thickened blood), which can have implications for both larger and smaller diameter vasculature. However, the most pronounced issues with the lack of compliance and fluidity declare themselves in the failure of the erythrocyte to deform itself when transiting arterioles, capillary beds, and venules. These vessels are smaller, and can become congested or blocked altogether. Studies have demonstrated that HS is related to deep vein thrombosis (DVT) and arterial cardiovascular disease for this reason. The spleen typically acts as a filter for blood, and targets pathogens and other damaged cells within circulation. Removing blood contaminants promotes entire-body homeostasis. The following facts about the spleen's role in normal body functioning are crucial to understanding the implications of HS on the overall health of the individual:

Carbon is present in all biological material including skeletal remains, charcoal and food residues and plays an integral role in the dating of materials, through radiocarbon dating. The ratio of different carbon isotopes naturally fluctuates over time, and, by analysing the composition of carbon dioxide (CO2) in ancient air bubbles trapped in ice cores, a chronological record of these fluctuations can be constructed. Primary producers (such as grasses) absorb and sequester CO2 during photosynthesis, these plants are then eaten by consumers (such as cows, and later humans) which inherit this same CO2 signature. Therefore, by matching the carbon isotope ratios from a sample to ratios from the ice core record, the sample can be assigned to a broad period. After death, an organism no longer absorbs CO2, 14C's instability causes its concentration to decrease over time The predictable rate at which this occurs is known as an element's decay rate.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Is SR9009 approved for human use?

No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.

Why is SR9009 banned in sport?

The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

Network